(Q36651648)

15 August 2017

1 reference

title

Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism? (English)

1 reference

15 August 2017

3

1 reference

15 August 2017

Ruth E Board

1

1 reference

PubMed ID

17100404

15 August 2017

Nick Thatcher

series ordinal

2

1 reference

15 August 2017

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

66

1 reference

15 August 2017

15

1 reference

15 August 2017

1919-1931

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200666150-00003

15 August 2017

0 references

cites work

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200666150-00003

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

12 December 2020

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

12 December 2020

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

12 December 2020

Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues

1 reference

12 December 2020

ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

1 reference

12 December 2020

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up

1 reference

12 December 2020

Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer

1 reference

12 December 2020

Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses

1 reference

12 December 2020

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

1 reference

12 December 2020

The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression

1 reference

12 December 2020

An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn

1 reference

12 December 2020

High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors

1 reference

12 December 2020

Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin

1 reference

12 December 2020

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

12 December 2020

Thalidomide is an inhibitor of angiogenesis

1 reference

12 December 2020

Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer

1 reference

12 December 2020

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

1 reference

12 December 2020

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

1 reference

12 December 2020

Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant

1 reference

12 December 2020

bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs

1 reference

12 December 2020

Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer

1 reference

12 December 2020

Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer

1 reference

12 December 2020

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types

1 reference

12 December 2020

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

Development of matrix metalloproteinase inhibitors in cancer therapy.

1 reference

12 December 2020

Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth

1 reference

12 December 2020

Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications

1 reference

12 December 2020

Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

12 December 2020

Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

1 reference

12 December 2020

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

1 reference

12 December 2020

Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients

1 reference

12 December 2020

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress

1 reference

12 December 2020

The proteasome: a suitable antineoplastic target

1 reference

12 December 2020

Early versus late chest radiotherapy in patients with limited-stage small cell lung cancer

1 reference

12 December 2020

Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Ran

1 reference

12 December 2020

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

12 December 2020

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial

1 reference

12 December 2020

In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways

1 reference

12 December 2020

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

1 reference

12 December 2020

72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells

1 reference

12 December 2020

Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer

1 reference

12 December 2020

Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicent

1 reference

12 December 2020

Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study

1 reference

12 December 2020

Expression and Prognostic Significance of Metalloproteinases and Their Tissue Inhibitors in Patients With Small-Cell Lung Cancer

1 reference

12 December 2020

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

1 reference

12 December 2020

Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer

1 reference

12 December 2020

Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma.

1 reference

12 December 2020

Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer

1 reference

12 December 2020

Proteasome inhibitors in lung cancer

1 reference

12 December 2020

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

12 December 2020

Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.

1 reference

12 December 2020

Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.

1 reference

12 December 2020

NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells

1 reference

12 December 2020

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

1 reference

12 December 2020

Matrix metalloproteinase inhibition: a review of anti-tumour activity

1 reference

12 December 2020

Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.

1 reference

12 December 2020

Differential response of MG132 cytotoxicity against small cell lung cancer cells to changes in cellular GSH contents

1 reference

12 December 2020

Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer.

1 reference

12 December 2020

High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy

1 reference

12 December 2020

Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma P

1 reference

12 December 2020

Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts

1 reference

12 December 2020

Immunohistochemical detection of Bcl-2 protein in small cell carcinomas

1 reference

12 December 2020

Phase II study of imatinib in patients with small cell lung cancer.

1 reference

12 December 2020

Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines

1 reference

12 December 2020

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

1 reference

12 December 2020

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

12 December 2020

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

1 reference

12 December 2020

Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines

1 reference

12 December 2020

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

12 December 2020

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer

1 reference

12 December 2020

European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.

1 reference

12 December 2020

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.

1 reference

12 December 2020

10.2165/00003495-200666150-00003

Identifiers

DOI

1 reference

PubMed ID

17100404

Dimensions Publication ID

15 August 2017

0 references

1 reference

PubMed ID

17100404